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Abstract: Vaccinia virus (VACV) is one of the most extensively-studied viruses of the Poxviridae
family. It is easy to genetically modify, so it has become a key tool for many applications.
In this context, reporter genes facilitate the study of the role of foreign genes introduced into
the genome of VACV. In this review, we describe the type of reporter genes that have been used
to generate reporter-expressing VACV and the applications of the recombinant viruses obtained.
Reporter-expressing VACV are currently employed in basic and immunology research, in the
development of vaccines and cancer treatment.
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1. Introduction
Since the first description of recombinant DNA techniques, many advances have been achieved in
the field of molecular biology and genetic modification. Currently, there is a wide variety of tools that
allow the genetic modification of animals, plants, bacteria and viruses [1–4]. The genetic modification
of viruses has become one of the best strategies for introducing nucleic acids into different cells, tissues
or even in in vivo models, given the high transfection efficiency and ease of carrying it out, compared
to chemical or physiological methods [5,6].
After the description of recombination events in cells infected with vaccinia virus (VACV) and
through recombinant DNA technology [7,8], VACV has become a suitable model for the generation
of recombinant virus vectors [9]. At first, the main purpose for introducing foreign genes into virus
genomes was basic research about the biology of the viruses both in vitro and in vivo. However, with
the latest technical advances and the higher understanding of the VACV viral cycle, virus genetic
modification is getting a wider spectrum purpose. Thus, they can also be used for the development
of vaccines or as oncolytic agents. This review aims to highlight the main aspects of the genetic
modification of VACV and the generation and application of reporter-expressing virus in this model.
2. Biology of VACV
VACV is the prototype member of the Poxviridae family, so most research of poxvirus has been
focused on its use [10]. VACV is a large DNA double-stranded virus, with a complex envelope. It was
the live vaccine used to eradicate smallpox and nowadays is also used as a viral vector for recombinant
vaccines and cancer therapy [9,11]. The VACV genome is one of the largest of all DNA viruses, with a
size of 190 kbp and about 250 encoding genes [12]. The genome has a high genetic compaction, with a
few intergenic and small non-coding regions. The coding regions are continuous, thereby not given to
splicing [13,14].
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VACV have a complete replicating cycle inside the cytoplasm of the host cell, even though it is a
DNA virus (Figure 1) [10]. This fact determines the genetic characteristics of the virus, being completely
independent of the replication and transcription machinery of the host cell. Once the virion infects the
host cell, the viral core is uncoated, and nearly 100 early viral genes are transcribed [15,16]. Early genes
produce the required enzymes for catalyzing the viral core breakdown, viral DNA replication and
the modulation of the host antiviral response [17]. Viral DNA begins to replicate inside the infected
host cell using viral enzymes at 3 h post-infection. As soon as the viral replication starts, transcription
of downstream genes encoding for regulatory proteins that induce the expression of the late genes
occurs. Late genes encode for proteins and enzymes required for the assembly of new viral particles.
After DNA and all viral proteins are synthesized, the process known as morphogenesis begins, which
results in the formation of the new virions [18,19]. These can be retained inside the cell until cellular
lysis or released to the environment by other mechanism [10,18].
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Figure 1. Diagram representative of the VACV infection cycle. The different steps of the VACV cycle
are indicated.
3. VACV as a Vector
Several features of the biology of VACV make it suitable for its use as a vector in biological
experiments, vaccine design or cancer therapy. The complete cytoplasmic replication of VACV
facilitates the expression of foreign genes inserted in the viral genome and its detection or
isolation [20,21]. Usually, bacterial or non-mammalian viral vectors fail to make the expressed proteins
to perform its full activity as antigens. However, VACV has the ability to transcribe its genes using
its own transcription factors and enzymes. That means that if a foreign gene is inserted directly to a
VACV promoter element, it will be transcribed with foreign proteins reaching high levels of expression
in the infected cell. Moreover, this replication cycle is an appropriate model for molecular and genetic
investigations of cis and trans factors that are mainly required for gene expression [12,22]. Furthermore,
since VACV remains in the cytoplasm, the risk of insertional mutagenesis and oncogenesis, the main
problems encountered in gene therapy using integrative viruses, disappears. In some cases, patients
treated with retroviral vectors have developed cancer years after they have been treated [5,23].
VACV can replicate in different cell lines, primary cell cultures, and also grows in several animal
species, such as mice, guinea pigs, rabbits, etc. [10]. This broad host range allows infection of cell lines
with recombinant viruses for large-scale expression of heterologous proteins, which reduces its cost in
comparison to other production systems [21,24]. Additionally, VACV enables high production titers,
so it is an advantage in the manufacturing of a large amount of vaccines [6].
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Although the VACV genome is large and compact, it can tolerate the deletion of certain viral
sequences and the insertion of exogenous genetic material [25]. A VACV vector has a transgene
capacity of approximately 25–30 kb, higher than other viral vectors, including adeno-associated virus
(4.5 kb), adenovirus (8–10 kb) and retrovirus (7–8 kb) [4]. Thus, VACV is an excellent candidate vector
in the design of polyvalent vaccines with antigens from several pathogens or different antigens from
the same pathogen [9,26].
Finally, as far as its use as a vaccine vector is concerned, VACV is clearly immunogenic effective,
strong evidence being the eradication of smallpox in 1980 [11]. VACV is also safe and easy to inoculate,
since it can be administrated intradermally or with an air gun without medical training. In some
organisms, it has been found that it can cause problems by preexisting immunity, but the probability
of having post-vaccination complications, such as progressive VACV infection or encephalitis, is
significantly low[27]. Nowadays, due to the better knowledge of the VACV biology and the immune
response generated after vaccination, vaccines based on this virus are becoming safer [9]. In addition,
it is important to remark that VACV vectors are very stable and can be lyophilized and kept frozen for
several years, facilitating its transport and storage [23].
4. Design Considerations in the Generation of VACV Vectors
To get recombinant VACV expressing foreign genes, the main method used is homologous
recombination (Figure 2) [28]. First, it is necessary to construct a plasmid that contains the gene
or transgene of interest. After that, the cells have to be infected with the virus and subsequently
transfected with the plasmid that contains the transgene. An alternative method could be used,
employing two viruses, one defective for some genes and one wild-type acting as a helper [4,29].
For both methods, the recombinant viruses are produced by homologous recombination inside the
infected cell.
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Figure 2. Construction of recombinant VACV vectors by homologous recombination. FG represents
the foreign gene and M represents the marker gene and TK: thymidine kinase gene. Adapted from [28].
Another way to generate recombinant viruses is the method described by Falkner and Moss [30],
denominated transient dominant selection (TDS), which allows the introduction of site-directed
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mutations into the VACV genome. Generally, the recombinant viruses obtained by this method are
rescued by metabolic selection, using the guanine phosphoribosyltransferase gene (gpt) from Escherichia coli
as a marker. The presence of the protein encoded by gpt allows the recombinant viruses to grow in
the presence of mycophenolic acid, xanthine and hypoxanthine [31]. Subsequently, after this first
metabolic selection, a second recombination event must occur to eliminate the selection marker,
maintaining the mutation introduced into the VACV genome (Figure 3) [32]. In contrast to the method
described above, in the TDS technique the marker should not be flanked by homologous regions of the
VACV genome [30]. Alternatively, puromycin resistance could be used as a selection marker in TDS,
increasing the recombinant viruses’ generation efficiency [33].
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Figure 3. Construction of recombinant VACV vectors by the transient dominant selection (TDS)
technique. FG represents the foreign gene and M represents the marker gene. R and L represent the
right and left flanking regions of the TK gene in the plasmid, and R’ and L’ represent the same regions
of the TK gene in the VACV genome. Adapted from [33].
Two important aspects to be considered when obtaining recombinant poxvirus are the VACV
genome insertion sites and the reporter genes introduced.
4.1. VACV Genome Insertion Sites
The VACV genome has about seven known insertion sites where foreign genes can be inserted
(Figure 4) [13]. The insertion site choice depends mainly on the future application of the recombinant
viruses. It may also be important in the later selection of the recombinant viruses obtained. For instance,
inserting the gene of interest in the thymidine kinase (TK) locus confers a detectable phenotype (TK-): the
recombinant viruses are able to grow in the presence of 5-bromo-2’-deoxyuridine (BrdU), a synthetic
analog of thymidine [28,34]. Another important site of insertion that allows a subsequent selection
is the VACV hemagglutinin (HA) gene as the recombinant viruses can be easily recognized by their
disability to bind erythrocytes in a hemagglutination test [35–37].
VACV has five more places of insertion: the BamHI site of the HindIII-F DNA fragment [38]; the
VACV growth factor gene (VGF), located in both inverted terminal repeats (ITRs) [39]; the N2 and M1
genes located on the left side of the VACV genome [40]; the M1 subunit of the ribonucleotide reductase
(RR) gene in the HindIII-I DNA fragment [41]; and the A27L gene encoding the 14 kDa fusion protein,
in the large HindIII-A DNA fragment [42]. It is noteworthy that some strains of VACV have only one
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copy of VFG, such as VACV Lister variants [33]. Recombinant production using these insertion sites,
although successfully occurring, requires the use of a marker gene or other strategies for later selection
of the recombinant viruses. Due to these limitations, the TK gene is the most common site of insertion
in the VACV genome [5]. Some authors have used temperature-sensitive VACV strains, allowing the
recombinant viruses to be selected in culture at 40 ˝C [43]. However, the most common way for an
easy identification of recombinant viruses is the use of reporter genes as selectable markers, which will
be discussed in Section 4.2 [44].Viruses 2016, 8, 134  5 of 18 
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Figure 4. Scheme of the insertion sites in the VACV genome. The diagram of the VACV genome with
the HindIII restriction sites is shown, including the location of the different insertion sites. BamHI:
BamHI site of the HindIII F fragment; HA: hemagglutinin gene; VGF: VACV growth factor gene; N2: N2
gene; M1: M1 gene encodes the large subunit of ribonucleotide reductase (RR); TK: thymidine kinase
gene; A27L: gene that encodes the 14 kDa fusion protein; ITRs: inverted terminal repeats. Adapted
from [13].
In spite of the promoter or the regions between the promoter and coding region, the insertion site
also influences foreign gene expression and virus virulence [13,23,25]. Insertion into the TK, VGF, RR
or A27L genes has an impact on viral replication in vivo, but not in vitro [25,45]. Moreover, the method
described in Figure 2 requires the use of special cell lines or mutagenic selective agents, such as TK-/-
cell lines and BrdU [30]. For this reason, different strategies and new insertion sites are being studied
to ensure the correct expression of the transgenes in vitro and in vivo [25,33,46,47].
4.2. Reporter-Exp ssing Viruses
Reporter-expressing viruses are recombinant viruses expressing a reporter gene [48]. In some
cases, the reporter gene is located downstream of a viral promoter, to study biological pathways or,
fused with other viral or foreign genes. As reporter genes are expected to be easily detected, they
are the best indicators for screening successfully recombinant viruses. The reporter gene should be
chosen considering the non-endogenous activity in the cell type, tissue or organism used to culture the
viruses [44]. Reporter genes have additional applications in vitro and in vivo, as the reporter gene acts
as a substitute of the gene of interest. Moreover, reporter genes facilitate the use of tissue-specific and
pathway-specific promoters, as well as regulatory promoter elements as biomarkers for a particular
event route. Furthermore, it is important that the existence of the reporter gene should not affect the
normal physiology and general characteristics of the transfected cells [48–50]. Table 1 presents an
overview of the reporter genes commonly used in the generation of recombinant VACV.
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Table 1. Reporter genes commonly used in the generation of recombinant vaccinia virus (VACV).
Reporter Gene Origin Product Detection Reference
CAT Escherichia coli Chloramphenicolacetyltransferase
Thin-layer chromatography
autoradiography, ELISA [51,52]
LacZ Escherichia coli β-galactosidase Colorimetry [53]
GUS Escherichia coli β-glucuronidase Colorimetry or fluorescence [54]
GFP Aequorea victoria(jellyfish) Green fluorescent protein Fluorescence [50,55]
LUC or luxCDABE Photinus pyralis (firefly)and bacteria Luciferase Luminescence [56,57]
ELISA: enzyme-linked immunosorbent assay.
4.2.1. Chloramphenicol Acetyltransferase
CAT was the first reporter gene used in transcriptional assays in mammalian cells. CAT
is an enzyme from Escherichia coli that detoxifies the antibiotic chloramphenicol, which inhibits
protein synthesis in bacteria [58]. Particularly, CAT links acetyl-coenzyme A (acetyl-CoA) groups to
chloramphenicol, preventing it from blocking the 50 S ribosomal subunit. This gene is not found in
eukaryotes, so eukaryotic cells do not present any basal CAT activity [44]. The reaction catalyzed by
CAT can be quantified using fluorogenic or radiolabeled substrates, such as 3H-labeled acetyl-CoA
and 14C-labeled chloramphenicol. CAT can be detected either by thin-layer chromatography,
autoradiography or enzyme-linked immunosorbent assay (ELISA) [51].
There is a strong link between CAT gene transcript levels and enzymatic activity, which is easy to
quantify. Thus, CAT has become a suitable reporter gene for investigating transcriptional elements in a
wide variety of experiments implicating animal and plant cells, as well as viruses [51]. There are some
disadvantages of using the CAT system, such as the higher amount of cells required when compared
to other assays, like the luciferase assay (detailed in Section 4.2.5). In addition, the CAT system is not
suitable for use with weakly-expressed genes and CAT promoter activity quantification takes longer
than other reporter systems [52]. Finally, this reporter gene has another important limitation due to the
use of radioisotopes [44].
4.2.2. β-Galactosidase
The first study using lacZ as a reporter gene was published in 1980, and since then, it has become
one of the most commonly-used reporter genes in molecular biology [49]. Although β-galactosidase
catalyzes the cleavage of the disaccharide lactose to form glucose and galactose, it recognizes several
artificial substrates, which has promoted its use as a reporter gene [58]. Thus, β-galactosidase can
hydrolyze substrates such as ortho-nitrophenyl beta-galactoside (ONPG), 5-bromo-4-chloro-3-indolyl
beta-D-galactopyranoside (X-Gal) and 3,4-cyclohexenoesculetin beta-D-galactopyranoside (S-Gal),
resulting in a yellow, blue or black product precipitate, respectively [53,59]. Furthermore, expression
of the lacZ gene can be stimulated with isopropyl beta-D-thiogalactopyranoside (IPTG), which is a
highly stable synthetic and non-hydrolyzable analog of lactose [49].
One of the applications of the lacZ reporter gene is the selection of transformed bacterial
colonies. The recombinant (white) and non-recombinant (blue) bacteria are discriminated based on
the interruption of the lacZ gene by the insert DNA or gene of interest using X-Gal as a substrate [53].
Other uses are the visualization of the β-galactosidase expression in transfected eukaryotic cells or
the selection of the recombinant virus by viral plaque screening [60]. Finally, lacZ is used to detect
β-galactosidase activity in immunological and histochemical experiments [44]. One of the main
advantages of using this reporter gene system is its low cost, since it does not require specific devices
to detect the colorimetric reaction or to identify its expression.
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4.2.3. β-Glucuronidase
Another Escherichia coli-derived hydrolyzing enzyme gene that lends a reporter assay is
GUS. The β-glucuronidase protein catalyzes the breakdown of complex carbohydrates, such
as glycosaminoglycans. This reporter gene system has been widely used in transgenic plants,
and it has also been successfully used in mammalian cells for VACV recombinant virus
selection [54]. For the β-glucuronidase (GUS) assay 4-methylumbelliferyl beta-D-glucuronide (MUG)
or 5-bromo-4-chloro-3-indolyl beta-D-glucuronide (X-Gluc) can be used as substrates. They respectively
lead to a fluorogenic or a blue product after cleavage [61,62]. Monitoring β-glucuronidase activity
through a GUS assay allows the determination of the spatial and temporal expression of the gene of
interest [63].
4.2.4. Florescent Proteins
The most known fluorescent protein is green fluorescent protein (GFP), which was cloned from
the species of jellyfish Aequorea victoria. Because of the great impact of fluorescent proteins in molecular
biology applications, the Nobel Prize in Chemistry 2008 was awarded to Osamu Shimomura, Martin
Chalfie and Roger Y. Tsien for the discovery and development of GFP [64,65]. GFP is the most used
reporter gene; however, genetic engineering has developed a wide variety of color mutants, such as
red fluorescent protein (RFP) or yellow fluorescent protein (YFP) among others [49].
Fluorescent proteins tolerate N- and C-terminal fusions to a wide-range of proteins, have been
expressed in most known cell types and are used as a non-harmful fluorescent marker in living
cells and organisms. The use of fluorescent proteins allows a variety of applications: cell lineage
tracker , reporter for gene expression assays or measure of protein-protein interactions. Additionally,
cell-fixation is not needed to examine its expression, and the probability of artifacts is quite small
compared to immunocytochemical methods which require cell fixation [44]. One of the disadvantages
of these proteins is their size. Therefore, in some cases, they can affect the in vivo function of fused
proteins or genes of interest. Nevertheless, one limitation of using GFP is its low sensitivity [66],
another is that its signal cannot be exogenously amplified [50].
4.2.5. Luciferases
The first luciferase (LUC), from the firefly Photinus pyralis, was cloned in 1980 and LUC has
been widely used as a reporter gene. Later, it was also described in bacteria and dinoflagellates [44].
Luciferases are enzymes that catalyze a chemical reaction resulting in the production of light. Firefly
luciferase oxidize the D-luciferin, in the presence of oxygen and adenosine triphosphate (ATP) as
the energy source. As in β-Galactosidase assays, an exogenous substrate is needed, and it may be a
disadvantage [49]. In other systems, such as the luciferase identified in bacteria (luxCDABE operon),
the enzyme catalyzes the oxidation of long-chain aldehydes and flavin mononucleotides (FMNH2)
in the presence of oxygen to yield green-blue light [67]. Although in bacteria this operon encodes all
components necessary for light emission, it is limited in mammalian cells. Therefore, the exogenous
substrate has to be added to improve the reaction [56]. Besides the different substrates required, each
luciferase system is categorized by having specific kinetics, with a particular detection and sensitivities
that require adjusting the experimental design [58,67].
The use of luciferase is extremely widespread in biological systems studies and includes cell
proliferation assays, protein folding/secretion analyses, in vivo imaging and control of in vivo viral
spreading [57,67–69]. The main advantage of using this system is its high sensitivity when compared
to other systems, such as CAT. Additionally, the LUC system is more direct, rapid and suitable when it
comes to weakly-expressed genes, and it can be used to quantify gene activity. One disadvantage of
the LUC system is the requirement of ultrasensitive charge-coupled device (CCD) cameras to detect
gene expression [56].
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5. Applications of Reporter-Expressing Viruses
5.1. In Vitro Applications
Reporter-gene assays have helped the pox virologists in basic research, for example for the study
of the location, structure and function of many VACV proteins during the infection cycle and their
interaction with proteins of the host cell [44,70]. As shown in Dvoracek and Shors [63], the GUS
reporter gene was used for deleting the D9R viral protein and selecting the recombinant viruses, with
the aim to understand the role of this protein in the viral life cycle. In addition, the lacZ gene has
typically been used mainly for the selection of recombinants [71]. Moreover, several studies have
reported the different transgenes’ insertion points and VACV promoters in which the recombinant
virus production was enhanced. These studies are essential for improvement of the development of
vaccines based on recombinant VACV [62,72].
On the other hand, fluorescent markers such as the GFP, YFP or luciferase are also useful for
labelling VACV replicative strains. These viruses have allowed the study of processes like the input
and output morphogenesis in virus-infected cells [68,69,73–76]. In these studies, fluorescence of certain
viral proteins allows us to study their interaction with other viral or cellular proteins [77]. Furthermore,
VACV is a clear example of how viruses have developed strategies to evade the immune response [78].
In this field, the generation of recombinant VACV with reporter genes is also useful to discern the
molecular mechanism by which VACV proteins manipulate the immune system of the host. Thus, in
Unterholzner et al. [79], the generation of a GFP-labeled recombinant VACV revealed that the C6 viral
protein acted as an immunomodulatory agent, blocking the expression of type I interferon.
Another major application of reporter-expressing VACVs is the design of high-throughput assays.
The generation of lacZ or GFP expressing recombinant virus can be used to optimize antibody
neutralization assays [71,80].
Lastly, VACV and reporter genes have been used to study proteins from other viruses, particularly
RNA viruses, such as influenza or severe acute respiratory syndrome-associated coronavirus
(SARS-CoV) [81]. To genetically modify these viruses, RNA must be reverse transcribed to cDNA,
since this is particularly unstable in plasmids, making VACV a good tool for functional studies of
proteins from such viruses [82].
5.2. In Vivo Applications
There are several in vivo applications for recombinant reporter-expressing viruses. For example,
in virulence studies, the use of labeled viruses allows us to follow the viral pathogenicity and detect in
which organs the viral replication and dissemination occur [70,76]. For example, Zaitseva et al. [69]
used the recombinant VACV Western Reverse strain (WR)-LUC to analyze the viral spread in vivo
for several days reducing the number of mice used. Moreover, VACV is an effective enhancer for
both humoral and cell-mediated immunity; it is used as a vector to study the immune system and the
expression of proteins’ antigenicity of other pathogens. Furthermore, VACV is used to explore the
immunopathological mechanisms, to know which epitopes or antigens presented by a pathogen have
the ability to induce the host-immune response, and to demonstrate the specific role of a particular
antigen during the pathogenic process [13,83,84].
Despite the examples mentioned above, the most common uses of recombinant VACV in vivo
are the production of prophylactic vaccines and treatments against cancer [4,85]. Table 2 shows some
of the vaccines based on VACV, with the reporter gene and the insertion site employed indicated
in each case. In these vaccines, VACV acts as a vector capable of delivering antigens from other
organisms [23]. While in many recombinant vaccines a viral antigen has been inserted, some of them
have also been developed against bacteria [86] or protists [34,87,88]. These vaccines simulate infection
by the pathogen from which the antigens are and elicit the immune response, by producing antigens
for different pathogens. In several vaccines, mainly against human immunodeficiency virus (HIV)
or influenza, genes of immunomodulatory cytokines are added for coexpression with the antigen,
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improving the immunogenicity of the vaccines [23,89,90]. As summarized in Table 2, most of the
transgene insertion sites are within the TK or the HA genes, making the selection of recombinants
easier, as explained above. However, in several vaccines, besides using this strategy, a reporter gene is
used as well. The use of reporter genes facilitates the preliminary tests of the vaccine on animal models.
Moreover, especially in vaccines used in animals, the reporter gene makes it possible to distinguish
between vaccinated and infected animals [48]. For example, VACV has been used for nearly twenty
years to eradicate rabies from wildlife as an oral-based vaccine. In this case, the recombinant VACV
expresses the rabies virus glycoprotein and has been used to vaccinate raccoons, red foxes, skunks and
coyotes in the United States and Europe. This battle has successfully purged rabies in some parts of
Europe and the United States [91].




Site of Insertion Reporter Gene
Viral
HIV
Env TK or HA gene LacZ, LUC [90,92]
Env (TAB 13) HA gene LacZ [35]
RT Not mentioned LacZ [93]
Hepatitis B virus
HBsAg TK gene or BamHI site Not mentioned [38,94,95]
PreS2-S TK gene Not mentioned [96]
LS TK gene Not mentioned [97]
MS TK gene Not mentioned [98]
Herpes simplex virus 1
gD TK gene or BamHI site Not mentioned [38,99,100]
gB Not mentioned Not mentioned [101,102]
gG Not mentioned Not mentioned [103]
Influenza
HA TK gene Not mentioned [104]
M1, NS1, NP, PB1, PA TK gene Not mentioned [105]
Protist
Plasmodium yoelii Circumsporozoite TK gene LacZ [34]
Plasmodium knowlesi Sporozoite antigen TK gene Not mentioned [88]
Plasmodium falciparum S antigen TK gene Not mentioned [87]
Leishmania infantum LACK TK and HA gene LacZ and GUS [106]
Animal Echinococcus granulosus E95 antigen TK gene LacZ [107]
Bacterial
Brucella abortus 18-kDa antigen TK gene LacZ [86]
Streptococcus pyogenes M protein TK gene Not mentioned [108]
Another application for VACV vectors is in cancer treatment, known as oncolytic virotherapy [26].
This is the use of replication-competent viruses to selectively attack and destroy cancer cells, without
harming healthy host cells [109]. Examples of recombinant VACV used are summarized in Table 3.
A promising study is the use of oncolytic VACV as a vector for the human sodium iodide symporter
(hNIS) gene in prostate cancer therapy, which has been demonstrated to restrict tumor growth and to
increase survival in mice [110]. VACV is also a promising therapeutic agent for pancreatic cancer [85],
cholangiocarcinoma [111] and colorectal cancer [112]. It is worth mentioning that many of the
viral vectors developed to treat tumors have several common characteristics. Generally, VACV
oncolytic vectors have a deletion in the TK gene, essential for the pyrimidine synthesis pathway,
which forces the virus to replicate in cells displaying a high amount of nucleotide pools, enhancing
the viral tropism to cancer cells. Others have a deletion in the VGF gene, preventing non-infected
cells from proliferation [109]. Furthermore, as in the development of vaccines, viral vectors are
“armed” with genes that enhance the antitumor activity, the virus tropism or the immunoreactivity, to
promote better tumor destruction, such as granulocyte-macrophage colony-stimulating factor (GM-CSF)
or erythropoietin genes (enhanced virus; Table 3). Another particular feature is that many of these
recombinants carry reporter genes, and thus viral replication can be monitored by non-invasive
imaging methods [68,69,76,113].
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TK, HA and F14.5L
inactive GFP, LacZ and GUS [111]
vvDD Sarcomas, neuroblastoma TK and VGF inactive CD [115,116]
Enhanced virus
GLV-1h153 Pancreatic cancer GLV-1h68 expressing hNIS [110]
GLV-1h210 Lung cancer GLV-1h68 expressing hEPO [117]
vvDD-SR-RFP Sarcomas, neuroblastoma TK and VGF inactive CD, RFP, SR [118]
6. Limitations of VACV Vectors
The main limitation of using VACV as a vector is the short-term gene expression, since it is
a lytic virus killing the infected cells. Thus, gene expression will not last for more than 12–24 h
post-infection [13,109]. Additionally, although for some applications it is an advantage, since VACV
replicates completely in the infected cell cytoplasm, it is hard to use VACV to engineer nuclear gene
replacement [23]. The other main disadvantage is the limited immunogenicity in individuals vaccinated
against smallpox. This pre-existing immunity reduces the effectiveness of vaccines based on VACV,
although some trials have overcome this problem by mucosal vaccination with vaccinia vectors [5].
The VACV safety profile should be considered because it has progressive complications especially with
immunocompromised individuals [11]. These limitations primarily affect in vivo applications of VACV
recombinants in vaccine development, so several attenuated strains of VACV are being generated [9].
7. New Perspectives
As for other viruses, the development of vaccines or oncolytic therapies based on VACV requires
the understanding of its pathogenesis and biology. Despite improvements in the vectors’ design,
such as the use of different promoters or insertion sites, homologous recombination has been almost
exclusively the way to obtain VACV recombinants [45]. Homologous recombination requires the use
of markers or reporter genes for selecting recombinants, which offers many disadvantages. Apart
from the physical space needed for the marker gene, which is limited in therapeutic virus, the use of
certain markers can introduce mutations or generate artifacts that are only found after an analysis of
the generated virus. Sometimes, these problems cannot be detected in vitro, but are very important to
overcome when these vectors are used in vivo on animal models [46,48].
In recent years, some strategies have been developed to avoid these risks using markers, or at
least to remove them from the final recombinant VACV. Rice and colleagues [45] described a double
selection method to improve the selection of recombinant VACV, so that a reporter or marker gene is
not necessary. A helper virus is used to rescue a recombinant VACV and is subsequently grown in
non-permissive cells to the helper virus; allowing the selection of a large percentage of recombinant
virions. However, the method that has certainly had an enormous importance in the modification of
genomes is the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated
protein 9 (Cas9) system. Briefly, the CRISPR/Cas9 system consists of an endonuclease (Cas9) employing
a guide RNA to generate a break in a target place of the genome, later to be repaired, either randomly
or precisely using a specifically designed “restful” template [119]. The effectiveness of this system
has been proven in different organisms, including viruses, such as herpes simplex virus (HSV) [120],
hepatitis B virus (HBV) [121] and HIV [76]. Currently, this technique is starting to be used also in
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VACV [47]. For example, this system has achieved the deletion of VACV virulence genes, such as A46L
and N1L. A46L and N1L are VACV intracellular proteins that inhibit nuclear factor-kappa B (NF-kB)
activation, so it is undesirable that they were present in VACV vectors with therapeutic purposes [78].
Furthermore, given the efficiency of the method, “reparative” vectors with excisable marker genes have
been designed. Therefore, recombinant viruses are effectively isolated, but eventually, the marker gene
is eliminated [46]. Given the simplicity of recombinant VACV by the CRISPR/Cas9 system generation,
an exponential increase of applications with better markers for basic research or without selectable
markers for clinical application is expected [119,120].
8. Concluding Remarks
In conclusion, the development of recombinant viruses is a promising therapeutic advance in
the biomedical field. In this sense, the use of reporter-expressing VACVs has become a fundamental
tool for a number of applications, in basic research, vaccine design and cancer therapy. As many of
these trials are still experimental, more information is required regarding the side effects of the viral
treatment. Continuing efforts are necessary to develop new reporter-expressing VACVs that are safer
and more effective for future therapies.
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GFP green fluorescent protein
gG glycoprotein G
GM-CSF granulocyte-macrophage colony-stimulating factor
gpt guanine phosphoribosyltransferase gene
GUS β-glucuronidase
HA hemagglutinin
HBsAg hepatitis B virus surface antigen
HBV hepatitis B virus
hEPO human erythropoietin
HIV human immunodeficiency virus
hNIS sodium iodide symporter
HSV herpes simplex virus
IPTG isopropyl beta-D-thiogalactopyranoside
ITRs inverted terminal repeats
LACK Leishmania homolog of activated C kinase
lacZ β-galactosidase gene
LS large surface protein
LUC luciferase
M1 matrix 1
MS middle surface protein
MUG 4-methylumbelliferyl beta-D-glucuronide
NF-kB nuclear factor-kappa B
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NP nucleoprotein
NS1 non-structural protein 1
PA polymerase acidic
PB1 polymerase basic 1
RT retrotranscriptase
ONPG ortho-nitrophenyl beta-galactoside
RFP red fluorescent protein
RR ribonucleotide reductase
SARS-CoV severe acute respiratory syndrome-associated coronavirus
S-Gal 3,4-cyclohexenoesculetin beta-D-galactopyranoside
SR somatostatin receptor




VGF vaccinia growth factor
WR Western Reserve strain
X-Gal 5-bromo-4-chloro-3-indolyl beta-D-galactopyranoside
X-Gluc 5-bromo-4-chloro-3-indolyl beta-D-glucuronide
YFP yellow fluorescent protein.
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